Balyasny Asset Management
SABSW icon

Balyasny Asset Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Balyasny Asset Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-281,107
Closed -$15.8K – 2730
2023
Q1 		$15.8K Hold
281,107
– – ﹤0.01% 2466
2022
Q4 		$16.7K Hold
281,107
– – ﹤0.01% 2499
2022
Q3 		$18K Hold
281,107
– – ﹤0.01% 2592
2022
Q2 		$42K Hold
281,107
– – ﹤0.01% 2390
2022
Q1 		$129K Hold
281,107
– – ﹤0.01% 2104
2021
Q4 		$503K Sell
281,107
-18,893
-6% -$34.7K ﹤0.01% 1617
2021
Q3 		$270K Buy
+300,000
New +$214K ﹤0.01% 1608

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Balyasny Asset Management's SABSW Position: Q2 2023 in Review

Balyasny Asset Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2023, closing a stake of 281,107 shares — an estimated $15.8K sold.

Balyasny Asset Management first reported a position in SABSW in Q3 2021 and held it in 7 quarters. The position peaked at $503K in Q4 2021. 10 funds tracked by Wall St. Rank hold SABSW as of Q2 2023.

  • Balyasny Asset Management reported no remaining SAB Biotherapeutics Warrant position as of Q2 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 281,107 SAB Biotherapeutics Warrant shares in Q2 2023, an estimated $15.8K.
  • Balyasny Asset Management first reported a position in SAB Biotherapeutics Warrant in Q3 2021 and held it in 7 quarters.
  • Balyasny Asset Management's SAB Biotherapeutics Warrant position peaked at $503K in Q4 2021.
  • 10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.